Syndrome  >>  Korlym (mifepristone)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Korlym (mifepristone) / Corcept Therap
SEISMIC, NCT00569582: A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome

Completed
3
50
US
mifepristone, CORLUX
Corcept Therapeutics
Cushing's Syndrome
01/11
 
NCT01371565: Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome

Completed
3
4
US
Mifepristone, CORLUX®
Corcept Therapeutics
Cushing's Disease, Cushing's Syndrome
06/12
09/12
NCT00936741: An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

Completed
3
30
US
mifepristone, CORLUX
Corcept Therapeutics
Cushing's Syndrome
09/12
09/12
NCT01925092: Mifepristone in Children With Refractory Cushing's Disease

Withdrawn
3
0
US
mifepristone, Korlym
Corcept Therapeutics, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Cushing's Disease
12/16
 

Download Options